fimepinostat

Fimepinostat is a synthetic, orally available small molecule that acts as a dual inhibitor of both class I phosphoinositide 3-kinase (PI3K) isoforms and pan histone deacetylase (HDAC) enzymes. By inhibiting these targets, fimepinostat blocks the PI3K-AKT-mTOR signaling pathway and HDAC activity, which are often overactivated in various cancer cell types. This dual inhibition can prevent tumor cell growth and induce apoptosis more effectively than targeting either pathway alone. Fimepinostat has demonstrated antineoplastic activity in preclinical models and clinical trials for several cancers, including lymphoma (notably diffuse large B-cell lymphoma), solid tumors, breast cancer, multiple myeloma, NUT midline carcinoma, thyroid cancer, gliomas, medulloblastoma, and others. It also shows potential as an HIV latency-reversing agent without inducing T cell activation or proliferation. The drug was developed by Curis and has received orphan drug designation for diffuse large B-cell lymphoma[1][2][3][4][5][6][7].

Other names

fimepinostat